Chemotherapy and its evolving role in the management of advanced prostate cancer
Advanced prostate cancer has been recognized as being responsive to androgen deprivation since the 1940s when Charles Huggins first described the role of surgical castration in managing these patients. However, androgen deprivation only results in transient disease control for the vast majority of m...
Main Authors: | Michael T Schweizer, Emmanuel S Antonarakis |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-06-01
|
Series: | Asian Journal of Andrology |
Subjects: | |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2014;volume=16;issue=3;spage=334;epage=340;aulast=Schweizer |
Similar Items
-
Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer
by: Janice Zhao, et al.
Published: (2023-08-01) -
Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer
by: Johann de Bono, et al.
Published: (2016-03-01) -
Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer
by: Gianpaolo Perletti
Published: (2016-03-01) -
Chemotherapy for hormone-resistant prostate cancer: Where are we today?
by: Tomas Buchler, et al.
Published: (2007-01-01) -
Critical appraisal of cabazitaxel in the management of advanced prostate cancer
by: Sumanta Kumar Pal, et al.
Published: (2010-12-01)